Home
  >  
Section 23
  >  
Chapter 22,777

Host neutralizing responses and pathogenesis of hepatitis C virus infection

Zeisel, M.B.; Cosset, Fçois-Loïc.; Baumert, T.F.

Hepatology 48(1): 299-307

2008


ISSN/ISBN: 0270-9139
PMID: 18508291
DOI: 10.1002/hep.22307
Accession: 022776025

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Biological therapeutic agents (biologicals), such as monoclonal antibodies (mAbs), are increasingly important in the treatment of human disease, and many types of biologicals are in clinical development. During preclinical drug development, cardiovascular safety pharmacology studies are performed to assess cardiac safety in accord with the ICH S7A and S7B regulations that guide these studies.

PDF emailed within 0-6 h: $19.90